Outlook Therapeutics, Inc. (OTLK)

Nasdaq: OTLK · Biological Products, (No Diagnostic Substances) · Iselin, NJ · filing with the SEC since 2015

Full chart Alerts Compare

Grade3.6

◀ Past 3.5● Present 2.4▶ Future 4.8

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Outlook Therapeutics, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.6/10

◀ Past3.525% of the headline

● Present2.435% of the headline

▶ Future4.840% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.5/1025% of the headline grade · 1 of 3 filed, 2 estimated

Surviving crises

as filed

1.7/10

Has it survived what it has been through?

14 warning events since 2017; the latest 2026-09-30.

weight 22% of this tense · 17th percentile among 159 sector filers · read for itself

From the record

Outlook Therapeutics, Inc.'s filings since 2017 show 14 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 13 times, the latest 2026-09-30); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2026-08-17) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate

4.9/10

What has it actually done, year after year?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 103 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 103 members with one.
What the record cannot read: Fewer than three filed years of revenue on file.
How it was reasoned: family median, 103 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Outlook Therapeutics, Inc.'s track record is put at 4.9 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 103 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

SI estimate

2.8/10

How has it treated the people who own it?

SI estimate 2.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 28th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 28% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Outlook Therapeutics, Inc.'s shareholder treatment is put at 2.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 28% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.4/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

1.3/10

Is it financially healthy right now?

Leverage 273%: owes 273¢ per asset dollar.

weight 45% of this tense · 13th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-09-30, Outlook Therapeutics, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 273 cents per dollar of assets, and net share issuance: its share count grew 87.6% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 6% of its family
gross profit against assetsbottom 16% of its family
the share count against the year beforebottom 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

2.0/10

How strong is its position in its industry?

bottom 21% of 102 in its family; net margin -4416.2%.

weight 22% of this tense · 21st percentile among 102 sector filers · read for its customers

From the record

Outlook Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $1 million in fiscal 2025 ranks in the bottom 22% by size; a net margin of -4416.2% ranks in the bottom 20% (its annual reports).

What it rests on

revenue against the family$1.4Mbottom 22% of its family
net margin-4416.2%bottom 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

4.1/10

What are the people in charge doing?

bottom 41% of 110 in its family for leadership; chief executive since 2025.

weight 33% of this tense · 41st percentile among 110 sector filers · read for its shareholders

From the record

Outlook Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Jahr, Robert Charles (Chief Executive Officer, as filed), filing under that title since 2025-07-09, 1.3 years (bottom 17% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 7.6 years (top 17%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 24%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge10 in three years among 12 peoplebottom 24% of its family
the median years the people in charge have filed7.6 yearstop 17% of its family
the chief executive's years on the record1.3 yearsbottom 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.8/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

as filed

4.3/10

How much room does it have to grow?

bottom 43% of 92 in its family for room to expand.

weight 33% of this tense · 43rd percentile among 92 sector filers · read for itself

From the record

Outlook Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $8 million against no long-term debt tagged leaves 43.5% of its assets as net cash, top 37% of its family; cash from operations less capital spending is -3666.7% of revenue (bottom 17%); a gross margin of 4% (bottom 12%); research spending of 1922.9% of revenue (top 20%) (its annual report).

What it rests on

cash less debt against assets43.5%top 37% of its family
cash from operations less capital spending against revenue-3666.7%bottom 17% of its family
gross margin4.0%bottom 12% of its family
research spending against revenue1922.9%top 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

SI estimate

4.9/10

What could actually drive growth from here?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 101 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 101 members with one.
What the record cannot read: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned: family median, 101 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Outlook Therapeutics, Inc.'s growth drivers is put at 4.9 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 101 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate

5.1/10

Did its newest year beat what its own record pointed to?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 73 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 73 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Outlook Therapeutics, Inc.'s expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton OTLK · research, not advice